Prevalence and description of chronic daily headache in the general population in France

Lantéri-Minet, Michel; Auray, Jean-Paul; Hasnaoui, Abdelkader El; Dartigues, Jean‐François; Duru, Gérard; Henry, Patrick; Lucas, Christian; Pradalier, A; Carrault, Guy; Gaudin, Anne-Françoise

doi:10.1016/s0304-3959(02)00348-2

Cited by 191 publications

(177 citation statements)

References 13 publications

Supporting

Mentioning

151

Contrasting

Unclassified

Order By: Relevance

“…A population-based questionnaire survey found a higher prevalence of medication overuse in the Netherlands but one of chronic headache without medication overuse corresponding well with our prevalence ( table 5 ) [13] . A French epidemiological study found that the prevalence of chronic migrainous and non-migrainous headache was higher than we have found [27] . Methodological and population differences can also account for some of these discrepancies.…”

Section: Comparison With Previous Studiescontrasting

confidence: 76%

Prevalence of Primary Chronic Headache in a Population-Based Sample of 30- to 44-Year-Old Persons

Grande¹,

Aaseth

Gulbrandsen

et al. 2008

Neuroepidemiology

View full text Add to dashboard Cite

Background: Prevalence data on primary chronic headache in the general population based on clinical interviews by physicians are lacking. Methods: In a cross-sectional epidemiological survey, a random sample of 30,000 persons from Akershus County, aged 30–44 years, were sent a postal questionnaire. Those with self-reported chronic headache within the last month and/or year were invited to a semi-structured diagnostic interview and a physical and neurological examination conducted by 2 neurological residents with experience in headache diagnostics. The diagnoses were made according to the International Classification of Headache Disorders, 2nd edition, 2004, and relevant revisions. Results: The questionnaire response rate was 71%, and the participation rate of the interview was 74%. The 1-year prevalence of primary chronic headache was 2.9%. Chronic tension-type headache (CTTH) and probable chronic tension-type headache (pCTTH) had 1-year prevalences of 1.6 and 1.2%, respectively. The prevalences of other primary chronic headaches were: chronic migraine (CM) 0.01%, probable CM 0.09% and other subtypes 0.04%. Co-occurrence of migraine was frequent, as 42% with CTTH and 55% with pCTTH had migraine. Conclusion: Primary chronic headache is prevalent in the general population. The majority has CTTH or pCTTH, while CM and other primary chronic headaches are rare.

show abstract

Section: Comparison With Previous Studiescontrasting

confidence: 76%

Prevalence of Primary Chronic Headache in a Population-Based Sample of 30- to 44-Year-Old Persons

Grande¹,

Aaseth

Gulbrandsen

et al. 2008

Neuroepidemiology

View full text Add to dashboard Cite

show abstract

“…The last year prevalence is approximately 10%-12% for migraine, 35%-68% for episodic tension-type headache and 4%-5% for chronic daily headache, including 2%-3% with chronic tensiontype headache (CTTH) and 1.5%-3% with medication overuse headache (MOH), when the 1988 IHS criteria and the CDH definition by Silberstein et al [2] are applied [8][9][10][11][12]. However, in clinical studies from specialised headache clinics, the picture is completely different.…”

Section: Epidemiologymentioning

confidence: 99%

“…In the latter group, a large proportion had drug overuse and probably also coexisting tension-type headache, although only one headache diagnosis was applied to each individ- Table 1 Common subtypes of chronic daily headache in relation to the diagnostic criteria of the International Headache Society (IHS), second edition [7]. In all the diagnostic groups, the headache should not be attributed to another disorder [12] reported the prevalence of CDH to be 2.98%, but although the authors mentioned that 84.4% of the patients used analgesics or acute migraine medication on a daily basis, they did not discuss the prevalence and considerable risk of medication overuse in this population. Such violations to the IHS classification system are fairly frequent and contribute considerably to the confusion in the area of chronic headache disorders.…”

Section: General Populationmentioning

confidence: 99%

Is chronic daily headache a useful diagnosis?

Jensen

Bendtsen

2004

J Headache Pain

View full text Add to dashboard Cite

The widely used term chronic daily headache is a common denominator for a chronic headache with a daily occurrence but is not included in the former and in the revised versions of the IHS classification system. We discuss the pros and cons for the use of the term chronic daily headache, and describe some of the problematic aspects in patients with chronic headaches. We find that the term should only be used as an unspecific, clinical working description and never as a final diagnosis due to lack of specificity. Most patients in specialized headache clinics suffer from several different primary and secondary headaches at the same time and deserve a careful characterization before a rational therapy can be initiated. In particular, it is of utmost importance to identify and treat coexisting medication overuse since such overuse may distort the clinical phenotypic presentation and render various prophylactic strategies ineffective. As the prognosis of medication overuse headache usually is favorable, identification of drug overuse is mandatory. The use of a wastebasket diagnosis such as chronic daily headache may obscure the precise headache diagnosis leading to an unsatisfactory treatment strategy and should therefore be avoided.

show abstract

“…Medication-overuse (MO) has been associated with the use of analgesics, opioids [2][3][4], ergot derivatives [5], and more recently, with triptans [2,3,[6][7][8][9][10]. MO is a secondary cause of chronic daily headache occurring in 4% of the population worldwide [11] and 3% of the French population [12]. Medication-overuse headache (MOH) is defined by the following criteria: headache present at least 15 days a month, regular intake (≥10 days per month for >3 months) of one or more anti-migraine drugs, occurrence or worsening of headache during medication overuse, and reversion to the previous pattern within 2 months after discontinuation of the overused medication [13].…”

Section: Introductionmentioning

confidence: 99%

Drug dependence associated with triptans and ergot derivatives: a case/non-case study

Beau-Salinas

Jonville-Béra

Cissoko

et al. 2009

Eur J Clin Pharmacol

View full text Add to dashboard Cite

Introduction The aim of this case/non-case study was to assess and compare the risk of drug dependence associated with different migraine-specific drugs, i.e., ergot derivatives and triptans, using the French pharmacovigilance database. Methods Reports on drug side effects recorded in this database between January 1985 and June 2007 were analyzed, and triptans (almotriptan, eletriptan, naratriptan, sumatriptan, and zolmitriptan) as well as ergot derivatives used in acute migraine were examined. For all reports, cases were defined as those reports corresponding to "drug abuse," "physical or mental drug dependence," and "pharmacodependence," whereas "non-cases" were defined as all the remaining SED reports. The method's reliability was assessed by calculating the risk associated with a negative (amoxicillin) and a positive (benzodiazepines) control. The risk of dependence associated with each drug and control was evaluated by calculating the odds ratio (OR) with a confidence interval of 95%. Results Among the 309,178 reports recorded in the database, drug dependence accounted for 0.8% (2,489) of the reports, with 10.9% (449) involving a triptan, and 9.33% (332) an ergot derivative. The risk of dependence was similar for triptans and ergot derivatives and did not differ from that of benzodiazepines. In the triptan group, the risk (odds ratio [95% CI]) ranged from 10. 3 [4.8-22.3] for sumatriptan to 21.5 for eletriptan [10.1-45.6], while in the ergot derivative group, it ranged from 12 [8-17.9] for ergotamine to 20.6 [8-53] for dihydroergotamine. Conclusions These findings confirm the hypothesis that triptans and ergot derivatives are associated with an increased risk of drug dependence.

show abstract

Prevalence and description of chronic daily headache in the general population in France

Cited by 191 publications

References 13 publications

Prevalence of Primary Chronic Headache in a Population-Based Sample of 30- to 44-Year-Old Persons

Prevalence of Primary Chronic Headache in a Population-Based Sample of 30- to 44-Year-Old Persons

Is chronic daily headache a useful diagnosis?

Drug dependence associated with triptans and ergot derivatives: a case/non-case study

Contact Info

Product

Resources

About